Teva Pharma, CureTech lymphoma drug Phase II trial meets primary endpoint
CT-011, an experimental anti-PD-1 monoclonal antibody, has also achieved secondary endpoint of overall survival (OS) in the Phase II trial. Initial analysis demonstrated that 70% of the patients
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.